Clarence L. Young

1.1k total citations · 1 hit paper
33 papers, 889 citations indexed

About

Clarence L. Young is a scholar working on Pharmacology, Surgery and Anesthesiology and Pain Medicine. According to data from OpenAlex, Clarence L. Young has authored 33 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pharmacology, 9 papers in Surgery and 7 papers in Anesthesiology and Pain Medicine. Recurrent topics in Clarence L. Young's work include Inflammatory mediators and NSAID effects (19 papers), Anesthesia and Pain Management (9 papers) and Pain Management and Opioid Use (6 papers). Clarence L. Young is often cited by papers focused on Inflammatory mediators and NSAID effects (19 papers), Anesthesia and Pain Management (9 papers) and Pain Management and Opioid Use (6 papers). Clarence L. Young collaborates with scholars based in United States, Canada and Germany. Clarence L. Young's co-authors include Frederick S. Southwick, Roy D. Altman, Paola Patrignani, Bill Bosch, Kay Brune, Guissou A. Dabiri, J. Rosenbloom, Annemarie Weber, Allan Gibofsky and Marc C. Hochberg and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Cell Biology and Hepatology.

In The Last Decade

Clarence L. Young

32 papers receiving 856 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology

2015 364 citations Roy D. Altman, Bill Bosch et al. Drugs profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Clarence L. Young United States	14	173	153	152	130	104	33	889
Patrice Muret France	17	61 0.4×	120 0.8×	50 0.3×	171 1.3×	140 1.3×	72	999
Sachiko Kamei Japan	19	87 0.5×	564 3.7×	126 0.8×	135 1.0×	41 0.4×	48	1.5k
Kalpana Joshi India	22	98 0.6×	531 3.5×	95 0.6×	42 0.3×	22 0.2×	69	1.6k
Gérard Fabre France	21	103 0.6×	391 2.6×	36 0.2×	61 0.5×	130 1.3×	58	1.4k
Ryoko Yumoto Japan	25	158 0.9×	654 4.3×	80 0.5×	108 0.8×	37 0.4×	96	2.3k
Karmen Stankov Serbia	20	70 0.4×	480 3.1×	56 0.4×	148 1.1×	39 0.4×	64	1.5k
Meijuan Zou China	24	164 0.9×	914 6.0×	65 0.4×	241 1.9×	23 0.2×	54	1.9k
Yuanyuan Zhang China	23	131 0.8×	467 3.1×	79 0.5×	102 0.8×	51 0.5×	90	1.3k
Xi Cao China	24	136 0.8×	614 4.0×	56 0.4×	163 1.3×	16 0.2×	70	1.7k
Kaoru Sakai Japan	23	181 1.0×	545 3.6×	102 0.7×	126 1.0×	78 0.8×	124	1.4k

Countries citing papers authored by Clarence L. Young

Since Specialization

Citations

This map shows the geographic impact of Clarence L. Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clarence L. Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clarence L. Young more than expected).

Fields of papers citing papers by Clarence L. Young

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clarence L. Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clarence L. Young. The network helps show where Clarence L. Young may publish in the future.

Co-authorship network of co-authors of Clarence L. Young

This figure shows the co-authorship network connecting the top 25 collaborators of Clarence L. Young. A scholar is included among the top collaborators of Clarence L. Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clarence L. Young. Clarence L. Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gharibo, Christopher, et al.. (2017). Opioid-sparing Effects of SoluMatrix Indomethacin in a Phase 3 Study in Patients With Acute Postoperative Pain. Clinical Journal of Pain. 34(2). 138–144. 1 indexed citations

Strand, Vibeke, Martin Bergman, Jasvinder A. Singh, et al.. (2017). Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial. Clinical Rheumatology. 36(6). 1357–1367. 2 indexed citations

Argoff, Charles E., et al.. (2016). SoluMatrix^®Diclofenac: Sustained Opioid-Sparing Effects in a Phase 3 Study in Patients with Postoperative Pain. Pain Medicine. 17(10). 1933–1941. 8 indexed citations

Altman, Roy D., Bill Bosch, Kay Brune, Paola Patrignani, & Clarence L. Young. (2015). Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology. Drugs. 75(8). 859–877. 364 indexed citations breakdown →

Gibofsky, Allan, et al.. (2015). Low-dose SoluMatrix diclofenac: a review of safety across two Phase III studies in patients with acute and osteoarthritis pain. Expert Opinion on Drug Safety. 14(8). 1327–1339. 2 indexed citations

Altman, Roy D., Marc C. Hochberg, Allan Gibofsky, Mark Jaros, & Clarence L. Young. (2015). Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study. Current Medical Research and Opinion. 31(12). 2331–2343. 21 indexed citations

Altman, Robin, et al.. (2015). Solumatrix diclofenac safety in older patients with osteoarthritis pain. Osteoarthritis and Cartilage. 23. A335–A336. 1 indexed citations

Desjardins, Paul J., et al.. (2014). Pharmacokinetic Properties and Tolerability of Low-dose SoluMatrix Diclofenac. Clinical Therapeutics. 37(2). 448–461. 19 indexed citations

Young, Clarence L., Vibeke Strand, Roy D. Altman, & Stephen Daniels. (2013). A Phase 2 Study of Naproxen Submicron Particle Capsules in Patients with Post-Surgical Dental Pain. Advances in Therapy. 30(10). 885–896. 4 indexed citations

10.

Manvelian, Garen, Marc C. Hochberg, Stephen E. Daniels, Roy D. Altman, & Clarence L. Young. (2013). A Phase 2 Study of Lower-dose, Indomethacin Submicron Particle Capsules Demonstrates Early Onset of Acute Pain Relief. Clinical Journal of Pain. 30(10). 846–851. 8 indexed citations

11.

Gibofsky, Allan, Mark S. Hochberg, & Clarence L. Young. (2013). A Phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis. Osteoarthritis and Cartilage. 21. S267–S267. 2 indexed citations

12.

Gibofsky, Allan, et al.. (2013). Lower-Dose Diclofenac Submicron Particle Capsules Provide Early and Sustained Acute Patient Pain Relief in a Phase 3 Study. Postgraduate Medicine. 125(5). 130–138. 18 indexed citations

13.

Argoff, Charles E., et al.. (2013). Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief in a phase 3 study in patients following bunionectomy surgery. Osteoarthritis and Cartilage. 21. S291–S291. 3 indexed citations

14.

Altman, Roy D., Stephen Daniels, & Clarence L. Young. (2013). Indomethacin Submicron Particle Capsules Provide Effective Pain Relief in Patients with Acute Pain: A Phase 3 Study. The Physician and Sportsmedicine. 41(4). 7–15. 13 indexed citations

15.

Tyring, Stephen K., Francisco Díaz‐Mitoma, Stephen D. Shafran, et al.. (2003). Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials. Journal of Cutaneous Medicine and Surgery. 7(6). 449–454. 10 indexed citations

16.

Manns, Michael P., P. Neuhaus, Gillian Atkinson, et al.. (2001). Famciclovir treatment of hepatitis B infection following liver transplantation: a long‐term, multi‐centre study. Transplant Infectious Disease. 3(1). 16–23. 18 indexed citations

17.

Man, Robert A. de, Patrick Marcellin, Flavio Habal, et al.. (2000). A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology. 32(2). 413–417. 65 indexed citations

18.

Trépo, C., et al.. (2000). Famciclovir in chronic hepatitis B: results of a dose-finding study. Journal of Hepatology. 32(6). 1011–1018. 21 indexed citations

19.

Southwick, Frederick S. & Clarence L. Young. (1990). The actin released from profilin--actin complexes is insufficient to account for the increase in F-actin in chemoattractant-stimulated polymorphonuclear leukocytes.. The Journal of Cell Biology. 110(6). 1965–1973. 78 indexed citations

20.

Young, Clarence L., et al.. (1966). Chlorination of Ground Water Supplies. American Water Works Association. 58(11). 1471–1474. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact